News Archive

Jay A. Perman will take over as chancellor of the University System of Maryland in January as Robert L. Caret steps down six months earlier than planned.

Caret had decided not to seek another five-year contract, and the system’s Board of Regents announced it had chosen Perman, the University of Maryland, Baltimore President, to succeed Caret in June.

But on Friday, the Board of Regents announced that University of Maryland, Baltimore’s provost and executive vice president, Bruce Jarrell, will take over as the interim president of the university early next year. In a letter to the University of Maryland, Baltimore community, Perman said that the Regents “has set my start date” as Jan. 6.

Image: https://www.umaryland.edu/

Ben Wu, the deputy secretary of the Maryland Department of Commerce, has been named as the new CEO for the Montgomery County Economic Development Corporation.

MCEDC is a public-private economic development nonprofit for the county.

The Montgomery County agency’s board of directors announced the appointment in a press release on Wednesday afternoon. Wu’s first day is Dec. 18.

Image: Ben Wu, Maryland’s deputy commerce secretary, has been named as the new CEO for the Montgomery County Economic Development Corporation. PHOTO FROM MONTGOMERY COUNTY ECONOMIC DEVELOPMENT CORPORATION

Newswise — The rise of additive manufacturing – or as it’s more commonly known, 3D printing – has enabled the rapid production of complex parts across many domains. As the techniques have become more refined, the semiconductor industry has taken note. But until recently, no one’s been able to form single-crystal materials – the building block of semiconductors – with traditional additive manufacturing processes.

Image: Johns Hopkins APL Takes 3D Printing of Electronic Parts to the Next Level

ROCKVILLE, Md., Dec. 2, 2019 /PRNewswire/ — Emmes today announced that it is part of a team of medical centers, universities and private industry supporting the development of a “universal influenza vaccine” that could provide longer-lasting protection than current vaccines and combat a wider variety of influenza viruses.

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the agreement, KSQ gains rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of KSQ’s engineered tumor-infiltrating lymphocyte (eTIL™) programs, which the company is developing for the treatment of PD-1 refractory solid tumors.

A Maryland-based biotechnology firm seems to have solved a puzzling issue for drug targeting and delivery that may usher in an era of gene therapies for neurological disorders. Rockville, Maryland’s REGENXBIO’s NAV Technology Platform provides the ability to treat neurological disorders by targeting specific disease-related genes or gene products. Their patented technology glides across the blood-brain barrier (BBB) without triggering the patient’s immune system as with unengineered adeno-associated virus (AAV)-derived vectors, providing localized gene delivery with few side effects.

Image: https://biobuzz.io

In May of 2018 Kite Pharma, a Gilead Company, announced the opening of a new Neo Antigen Facility in Gaithersburg, MD. Less than one year later in April of 2019, the company, announced that it was building a new biomanufacturing facility on a 20-acre site in Frederick, MD. Since then, Kite has been diligently working to build a world-class leadership team at both sites to achieve an important mission.

Image: https://biobuzz.io

EMMes has announced the development of a vaccine for the flu that is “universal influenza vaccine”.  EMMes is the part of a team including medical centers, private industry, and universities that support the development of a vaccine. The vaccine provides protection for a long time as compared to currently available vaccines. Moreover, it is capable to fight against a wide range and variety of influenza. The news was announced in ROCKVILLE on Dec 2, 2019.

Image: https://askhealthnews.com

Full-house, standing room only at our ‘Launching Life Sciences Innovation in Baltimore’ event co-hosted by LifeBridge Health and The LaunchPort at Rye Street Tavern. Thank you to MARYLAND BUSINESS INCUBATION ASSOCIATION and Weller Development for your support.

Image: https://www.linkedin.com

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Dental and Craniofacial Research (NIDCR) on behalf of the NIH.